Next Article in Journal
Human Milk Processing and Its Effect on Protein and Leptin Concentrations
Previous Article in Journal
Multi-Nutrient Analysis of Dietary Macronutrients with All-Cause, Cardiovascular, and Cancer Mortality: Data from NHANES 1999–2014
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 15
Issue 2
10.3390/nu15020346
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Differential Regulation of Glucosylceramide Synthesis and Efflux by Golgi and Plasma Membrane Bound ABCC10

by
Jahangir Iqbal
*,
Abeer Al Otaibi
,
Sindiyan Alshaikh Mubarak
,
Ali Alqarni
and
Ahmed Bakillah
King Abdullah International Medical Research Center-Eastern Region, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Hospital, Ministry of National Guard-Health Affairs, Al Ahsa 31982, Saudi Arabia
*
Author to whom correspondence should be addressed.
Nutrients 2023, 15(2), 346; https://doi.org/10.3390/nu15020346
Submission received: 1 November 2022 / Revised: 20 November 2022 / Accepted: 21 November 2022 / Published: 10 January 2023
(This article belongs to the Section Lipids)
Browse Figures
Versions Notes

Abstract

:
Glucosylceramide (GlcCer) synthesis by the enzyme glucosylceramide synthase (GCS) occurs on the cytosolic leaflet of the Golgi and is the first important step for the synthesis of complex glycosphingolipids (GSLs) that takes place inside the lumen. Apart from serving as a precursor for glycosylation, newly synthesized GlcCer is also transported to the plasma membrane and secreted onto HDL in the circulation. The mechanism by which GlcCer is transported to HDL remains unclear. Recently, we showed that ATP-binding cassette transporter protein C10 (ABCC10) plays an important role in the synthesis and efflux of GlcCer in Huh-7 cells. In this study, we found that treatment of Huh-7 cells with an ABCC10 inhibitor, sorafenib, decreased the synthesis and efflux of GlcCer. However, treatment of cells with cepharanthine reduced only the efflux, but not synthesis, of GlcCer. These results indicate that ABCC10 may regulate the synthesis and efflux of GlcCer differentially in liver cells.

1. Introduction

Sphingolipids are important bioactive components of cells that play a critical role in several metabolic and hormonal pathways. Studies on sphingolipids have intensified in the past decade. Much is known about the synthesis and signaling activities of sphingolipids [1,2,3,4,5]. The control of sphingolipid synthesis is regulated by various enzymes [6,7,8], beginning at the cytosolic leaflet of the endoplasmic reticulum (ER) to generate ceramide (Cer). Cer is a membrane-bound molecule that is transported via vesicular transport or by the protein ceramide transfer protein (CERT) from the ER to the Golgi apparatus, where it acts as a precursor for the synthesis of other complex sphingolipids such as sphingomyelin (SM), GlcCer, etc. (Figure 1) [9]. Synthesis of GlcCer is an important first step for the synthesis of other GSLs and is catalyzed on the cytosolic side of the Golgi by the transmembrane enzyme GCS [9,10,11]. Once GlcCer is synthesized in the cytosol, it is translocated towards the Golgi lumen for the synthesis of other GSLs by multiple Golgi and Trans Golgi Network flippases [9,11,12,13]. Recently, it was shown that multiple ABC transporters differentially regulate GSL biosynthesis by acting as GlcCer flippases [14]. Furthermore, ABCC1 and ABCA12 have been shown to transport GlcCer in vitro [15] and in keratinocytes [16].
We have shown previously that ATP-binding cassette family A protein 1 (ABCA1) deficiency in humans and mice reduces plasma GlcCer levels [17]. However, induction, downregulation, inhibition, or knockdown of ABCA1 in human hepatoma Huh-7 cells had no effect on GlcCer efflux to HDL [17]. Recently, we identified that ABCC10 plays a role in the synthesis and efflux of GlcCer in Huh-7 cells [18], and ABCA1 may indirectly affect plasma GlcCer levels by playing a role in the biogenesis of HDL. We hypothesized that ABCC10 may act as a flippase of GlcCer and, therefore, regulate its synthesis and efflux. To test this possibility, we used different inhibitors of ABCC10 and studied their effects on the synthesis and efflux of GlcCer in Huh-7 cells.

2. Materials and Methods

2.1. Materials

C6-NBD ceramide (catalog #6224) was purchased from Setareh Biotech (Eugene, OR, USA). Tamoxifen (catalog #T5648) was purchased from Millipore Sigma (St. Louis, MO, USA). Cepharanthine (catalog #sc-39121) and sorafenib (catalog #sc-220125) were purchased from Santa Cruz (Dallas, TX, USA). All other chemicals and solvents were obtained from Fisher Scientific (Pittsburgh, PA, USA) or VWR International (Bridgeport, NJ, USA).

2.2. Mice

The ABCC10 knockout mice on C57BL6/J background [19] were a kind gift from Dr. Elizabeth Hopper-Borge of Fox Chase Cancer Center, Philadelphia, PA. Mice were housed under a 12:12 h light:dark schedule and bred at the animal facility in accordance with all requirements of KAIMRC IACUC. Mice had ad libitum access to chow diet and water.

2.3. Synthesis and Efflux of Sphingolipids

For efflux, Huh-7 cells were incubated with 2 µM C6-NBD ceramide in 10% FBS containing DMEM at 37 °C for 3 h, washed 3 times with DMEM plus 0.1% BSA, and the efflux was initiated by the addition of fresh DMEM containing 40 µg/mL of either BSA or human serum HDL (#MBS173147, MyBioSource, San Diego, CA, USA). Culture media were collected after 6 h of incubation and centrifuged (2500 rpm, 600× g, 15 min, 4 °C, Heraeus Fresco 21 Centrifuge, 75003424 rotor, ThermoFisher Scientific, Waltham, NJ, USA) to pellet detached cells. To study the effect of tamoxifen on GlcCer synthesis, Huh-7 cells were treated with different doses (0–10 µM) of tamoxifen for 17 h before the addition of C6-NBD ceramide to the cells. In subsequent experiments, Huh-7 cells were treated with 5 µM concentration of sorafenib or cepharanthine for 17 h before the addition of C6-NBD ceramide or during the efflux studies with HDL. Lipids in the media and cells were extracted [20], dried and re-suspended in 100 µL of isopropanol for the separation of sphingolipids on thin layer chromatograph (TLC) silica plates (#44931, Analtech, Inc., Newark, DE, USA) using a CHCl3:CH3OH:C6H5CH3:NH4OH:H2O (40:40:20:0.4:1.6, ratios by volume) solvent system [17,21]. The TLC plates were visualized with the ChemiDoc MP Imaging System from BioRad (Hercules, CA, USA), and bands corresponding to Cer, SM, and GlcCer were quantified using ImageJ software version 1.53t (NIH, Bethesda, MD, USA).

2.4. Cell-Free In Vitro GlcCer Synthesis Assay

Liver tissues from chow-fed Abcc10+/+ and Abcc10−/− mice were homogenized in a buffer containing 50 mM Tris-HCl, 1 mM EDTA, 5% sucrose, pH 7.4 and a mixture of protease inhibitors. To study the effect of tamoxifen, a GlcCer synthesis assay was performed in liver homogenates from Abcc10+/+ and Abcc10−/− mice in the presence of different doses (0–10 µM) of tamoxifen for 1 h. In a separate assay, liver homogenates isolated from wildtype mice were incubated with 5 µM concentration of ABCC10 inhibitors, sorafenib or cepharanthine. The homogenates (500 µg of protein) were added to assay buffer containing 50 mM Tris-HCl, pH 7.4, 25 mM KCl, C6-NBD ceramide (3.3 µg/mL), phosphatidylcholine (100 µg/mL), and UDP-glucose (500 µM) in a total volume of 200 µL reaction and incubated for 1 h at 37 °C [22,23]. The reaction was stopped by adding 200 µL of CHCl3/CH3OH (2:1, v/v). Lipids were extracted and subjected to TLC.

2.5. Subcellular Fractionation and Western Blotting

Livers (~200 mg) from wildtype mice were washed with ice-cold PBS and minced on ice using sharp scissors. Tissues were resuspended in 2 mL of homogenization buffer (0.25 M sucrose, 1 mM EDTA, 15 mM HEPES, pH 7.4) containing 1 mM PMSF and homogenized using Kontes Potter-Elvehjem homogenizer (DWK Life Sciences, Mainz Germany) with ~20 iterations of up and down passes of the pestle. Homogenate was centrifuged at 1000× g for 10 min at 4 °C (Heraeus Fresco 21 Centrifuge, 75003424 rotor, ThermoFisher Scientific, Waltham, NJ, USA). Supernatant was collected and centrifuged for another 60 min at 10,000× g at 4 °C. For density gradient separation, 2 mL of 80%, 60%, 40%, and 20% Percoll (#17-0891-01, GE Healthcare, Chicago, IL, USA) in HEPES/sucrose buffer (0.25 M sucrose, 15 mM HEPES, pH 7.4) were layered on top of a 1 mL cushion of saturated sucrose. The 10,000× g supernatant from the above tissue homogenate was diluted to 3 mL with the homogenization buffer and layered on top of the Percoll gradient solutions. Samples were ultracentrifuged at 284,000× g for 2 h at 4 °C (Himac CP100NX, P40ST rotor, Eppendorf Himac Technologies Co., Ltd., Ibaraki, Japan), and 500 µL fractions were collected from the top. Fractions were sonicated on ice using two 10 second pulses with a 30 second interval and applied to SDS-PAGE gel. Gels were blotted onto PVDF membrane and analyzed with ABCC10 (#ab230017, Abcam, Waltham, MA, USA) or the indicated housekeeper protein marker antibodies (Pan-Cadherin #4068; GM130 #12480; Calreticulin #12238; Vimentin #5741; GAPDH #5174, Cell Signaling Technology, Danvers, MA, USA). Proteins were visualized after applying specific secondary HRP-conjugated antibodies and exposure to Clarity Western ECL substrate (#1705060, BioRad, Hercules, CA, USA) by use of a ChemiDoc MP Imaging System from BioRad (Hercules, CA, USA).

2.6. Statistical Analysis

Data were plotted as replicates and were presented as the mean ± S.D. The mean values of each group were analyzed by Student’s t test using GraphPad Prism software (version 5.0; GraphPad, San Diego, CA, USA). The results with p < 0.05 were considered statistically significant.

3. Results

3.1. Tamoxifen Decreases GlcCer Synthesis and Efflux in Huh-7 Cells

Treatment of Huh-7 cells with increasing doses (0–10 µM) of tamoxifen for 17 h resulted in an increase in the efflux of Cer and SM to both BSA and HDL acceptors (Figure 2A). As expected, the increase in efflux of Cer and SM was higher in HDL-treated cells compared to that in BSA-treated cells at all doses tested. Interestingly, tamoxifen decreased the efflux of GlcCer to both BSA and HDL. These results suggest that tamoxifen differentially affects efflux of Cer, SM and GlcCer. Next, we measured the levels of sphingolipids in the cells. We did not detect much difference in the cellular levels of Cer and SM with the increasing doses of tamoxifen. However, compared to BSA-treated cells, levels of Cer and SM in HDL-treated cells were lower (Figure 2B). Treatment of Huh-7 cells with tamoxifen resulted in a dose-dependent decrease in the levels of GlcCer in the cells treated with BSA or HDL, suggesting that tamoxifen also decreases the synthesis of GlcCer in the cells.

3.2. Tamoxifen Does Not Affect Glucosylceramide Synthase Activity in Liver Homogenates

To rule out the possibility that tamoxifen may be inhibiting the GCS enzyme, we performed the cell-free assay in the liver homogenates isolated from Abcc10+/+ and Abcc10−/− mice. Incubation of NBD-Cer with UDP-glucose and increasing doses of tamoxifen (0–10 µM) for 1 h with the liver homogenates from Abcc10+/+ and Abcc10−/− mice did not show any significant difference in the synthesis of GlcCer or SM (Figure 3). Furthermore, we did not see any difference in the synthesis of GlcCer or SM in the liver homogenates isolated from the Abcc10+/+ and Abcc10−/− mice. These combined data suggest that decrease in GlcCer levels in tamoxifen treated cells is not due to any reduction in GCS activity.

3.3. GlcCer Synthesis Is Decreased by ABCC10 Inhibitor Sorafenib but Not by Cepharanthine

To confirm that the decrease in GlcCer synthesis with tamoxifen in Huh-7 cells involves ABCC10, we pre-treated Huh-7 cells with a 5 µM concentration of known ABCC10 inhibitors, sorafenib and cepharanthine [24] for 17 h. Next, we labeled the cells with C6-NBD ceramide for another 3 h in the presence or absence of these inhibitors to study the synthesis of sphingolipids. Media were also collected to measure the secretion of sphingolipids. We did not see any change in the levels of Cer in the media but saw a decrease of ~19% in the levels of SM in the sorafenib-treated cells (Figure 4A). There was also a significant reduction of around 45–50% in the levels of GlcCer in the media in sorafenib- and cepharanthine-treated cells. Next, we measured the amount of these sphingolipids in the cells. Treatment of Huh-7 cells with either sorafenib or cepharanthine did not result in any significant change in the cellular levels of Cer or SM (Figure 4B). However, we saw a reduction of ~40% in the levels of GlcCer when the cells were treated with sorafenib as compared to DMSO-treated cells (Figure 4B), suggesting that GlcCer synthesis is affected by sorafenib. Surprisingly, cepharanthine was unable to reduce the levels of GlcCer in the cells. On the contrary, we saw an increase of ~83% in the levels of GlcCer in cepharanthine-treated Huh-7 cells when compared to DMSO-treated cells (Figure 4B). These results suggest that cepharanthine affects only the secretion of GlcCer to the media, resulting in its accumulation in the cells.
The differential effect of sorafenib and cepharanthine on the levels of GlcCer in Huh-7 cells was intriguing. The data suggest that pre-treatment of Huh-7 cells with sorafenib decreases both the synthesis and efflux of GlcCer, whereas cepharanthine only inhibits the efflux. To rule out the effect of reduced sphingolipid synthesis on the efflux, we did not pre-treat Huh-7 cells with the inhibitors before or during the incubation with NBD-Cer to allow for the synthesis of GlcCer. Cells were treated with the 5 µM concentration of inhibitors only during the efflux of the sphingolipids in the media. There was a significant decrease of ~29–35% in the efflux of GlcCer in the media after the treatment of Huh-7 cells with both the inhibitors (Figure 5A). We also saw a significant increase of more than 2-fold in the accumulation of GlcCer levels in the cells after the treatment with both sorafenib and cepharanthine (Figure 5B). These data suggest that sorafenib and cepharanthine act as GlcCer efflux inhibitors in the cells. Furthermore, treatment of cells with sorafenib after the allowing for the synthesis of sphingolipids did not affect the synthesis of GlcCer.
Changes in the levels of GlcCer in Huh-7 cells after the treatment with sorafenib or cepharanthine may be due to the changes in the activity of GCS. To test this possibility, we incubated liver homogenates isolated from wildtype mice with 5 µM concentration of either sorafenib or cepharanthine. In vitro cell-free assay showed that this change in GlcCer levels after the treatment with these inhibitors was not due to any change in the activity of GCS enzyme (Figure 6). These results suggest that sorafenib and cepharanthine are affecting GlcCer levels independent of GCS activity.

3.4. Localization of ABCC10 with Subcellular Membranes

One of the plausible explanations for the differential effect of sorafenib and cepharanthine on the synthesis of GlcCer may be because these inhibitors are inhibiting ABCC10 at different subcellular localizations in the cells. To show that ABCC10 is localized at different subcellular membranes in the cells, we performed Percoll gradient subcellular fractionation of mouse liver homogenate to isolate different membranes and used housekeeper protein markers to identify these fractions (Figure 7). Our data showed that ABCC10 is expressed in cell membrane as well as other subcellular membranes such as ER and Golgi.

4. Discussion

We recently reported that ABCC10 plays an important role in the synthesis and secretion of GlcCer [18]. Budani et al. [14] showed that multiple ABC transporters potentially act as GlcCer flippases and differentially control GSL biosynthesis. Here, we showed that ABCC10 differentially regulates the synthesis and efflux of GlcCer in Huh-7 cells. We hypothesize that Golgi-bound ABCC10 may be involved in GlcCer synthesis, whereas cell membrane-bound ABCC10 may be involved in GlcCer efflux.
Several studies have shown that multi-drug resistant (MDR) cells exhibit abnormal elevation of the GlcCer level, which is reduced by tamoxifen treatment [25,26,27]. Studies have revealed that elevated levels of GlcCer in cancer cells correlate with overexpression of P-glycoprotein [25,28]. Tamoxifen has been shown to bind and antagonize P-glycoprotein [29,30,31]. It is now well-known that these cell lines express increased levels of ABCC10 that confer resistance to a variety of anticancer drugs [32,33,34]. These observations suggest that increased ABCC10 expression may also be involved in increased GlcCer levels in MDR cells. Our data are consistent with these published reports showing reduced GlcCer synthesis in the presence of tamoxifen. This decrease in GlcCer synthesis is not due to reduction in GCS enzyme activity, since cell-free in vitro assays in liver homogenates from Abcc10+/+ and Abcc10−/− mice did not result in the inhibition of GCS. These results were again consistent with the published data showing that the synthesis of GlcCer was not inhibited by tamoxifen in the cell-free GCS assay using C6-ceramide as a substrate [31].
Sorafenib is a multi-kinase inhibitor [35] that inhibits the cellular efflux function of ABC transporters [36]. On the other hand, cepharanthine directly interacts with P-glycoprotein and inhibits its transport activity [37,38]. However, both sorafenib and cepharanthine have also been used to inhibit the ATPase activity of ABCC10 [24]. During prolonged pre-treatment of cells with sorafenib, we saw a reduction in both the cellular and media GlcCer levels. In contrast, prolonged pre-treatment with cepharanthine increased the levels of GlcCer in the cells and reduced the levels in the media. However, when cells were allowed to synthesize sphingolipids from NBD-Cer without the pre-treatment with these inhibitors, we observed that both sorafenib and cepharanthine, as expected, decreased the efflux of newly synthesized NBD-GlcCer to the media. Surprisingly, sorafenib, instead of decreasing the synthesis, increased the levels of GlcCer in the cells, similarly to cepharanthine. One plausible explanation for the differential effects of these two inhibitors on the synthesis and efflux of GlcCer may be due to the localization of ABCC10 on the cell plasma membrane and Golgi apparatus. Cell-free assays showed that the reduction in GlcCer levels in the cells was not due to inhibition of GCS enzyme activity. On the contrary, sorafenib treatment has been shown to increase the expression of both mRNA and protein levels of GCS in Hep3B and HepG2 cells [39]. These data suggest that changes in GlcCer levels in Huh-7 cells due to treatment with sorafenib or cepharanthine may be independent of the activity or protein levels of GCS enzyme. Studies have shown that GlcCer synthesis by GCS occurs on the cytoplasmic leaflet of the Golgi apparatus [11,40,41]. In this study, subcellular fractionation of liver cells showed that ABCC10 is located on both the cell membrane as well as subcellular membranes such as ER and Golgi (Figure 7).
Under normal conditions, GlcCer synthesized on the cytosolic side of the Golgi must be translocated to the lumenal side for further GSL biosynthesis (Figure 8A). It is presumed that translocation of GlcCer from the cytosol to lumen is mediated by multiple Golgi and Trans Golgi Network flippases [9,11,12,13]. It is possible that ABCC10 present on the Golgi membrane may also act as one of the flippases. Some of the GlcCer may be effluxed out of the cells to the media by ABCC10 (Figure 8A). Down-regulation of ABCC10 with siRNA [18] or inhibition with sorafenib or tamoxifen may decrease the flippase activity of ABCC10 on the Golgi membrane, causing a feedback inhibition of GCS, leading to reduction in GlcCer synthesis in the cells, as has been shown with other transporter proteins such as ABCA3, ABCA4, ABCB10, ABCA12, and ABCB1 [14]. We have previously shown that microsomal triglyceride transfer protein (MTP) enhances cellular cholesteryl esterification by relieving the product inhibition of ACAT enzymes by transferring the products from the enzymes’ active site onto the apoB-containing lipoproteins [42]. In these studies, we showed that deletion or inhibition of MTP leads to accumulation of cholesteryl esters (products of ACAT enzymes) in the intestinal and liver cells, causing feedback inhibition of ACAT enzymes. Based on these studies and similarly to MTP, we presume that flippases may be important in removing GlcCer from the site of its synthesis on GCS enzyme and transferring it to the Golgi lumen. We speculate that any reduction in the activity of these flippases may lead to the feedback inhibition of the GCS enzyme and, thereby, reduce GlcCer synthesis in the cells. When cells are treated with sorafenib, it not only binds to the cell surface ABCC10, but due to its higher bioavailability (~39–48%) [43], it can enter the cells and bind to the subcellular membrane ABCC10 and, thereby, decrease both efflux of GlcCer to the media and translocation of GlcCer to the lumen of the Golgi, leading to less synthesis due to feedback inhibition of GCS (Figure 8B). On the other hand, it is possible that due to low compound bioavailability (~5%) [44], cepharanthine may fail to enter the cells and binds only the ABCC10 on the cell membrane to reduce the efflux of GlcCer to the media, consequently causing accumulation of GlcCer inside the cells (Figure 8C). Reduction in the synthesis of GlcCer in the presence of sorafenib and not cepharanthine suggests that Golgi membrane and not cell membrane ABCC10 may play a role in the synthesis of GlcCer.
In summary, we identified a novel role of ABCC10 in the biosynthesis and transport of GlcCer across the membranes. Our studies provide evidence that ABCC10 may act as a flippase that translocates GlcCer across the Golgi membrane.
We also observed that Golgi membrane-bound ABCC10 plays a role in the synthesis and transport of GlcCer that may be an important step for further glycosylation to synthesize other GSLs inside the Golgi lumen. Further studies are warranted to elucidate the exact mechanism of ABCC10 as flippase of GlcCer during the synthesis of GSLs.

Author Contributions

J.I. designed and conceptualized the experiments and performed all data analysis. J.I., S.A.M., A.A.O. and A.B. performed the inhibitor and product inhibition experiments in Huh-7 cells. A.A. provided valuable insights and directions in the inhibitor studies. J.I. produced the figures and wrote the first draft of the manuscript. All authors read these drafts and conveyed their comments to J.I. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported in part by KAIMRC grants RA16/024/A, RA17/013/A and the Ministry of Education (MoE) grant RA20/005/A (project # 230) to J.I. The contents of this paper do not represent the views of the Saudi Arabia Government.

Institutional Review Board Statement

The animal study protocol was approved by the Institutional Animal Care and Use Committee of KAIMRC (Protocol #s RA17-013-A and RA20-005-A).

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Acknowledgments

We thank M. Mahmood Hussain of NYU Long Island School of Medicine, New York for providing ABCC10 knockout mice. We also thank Elizabeth Hopper-Borge of Fox Chase Cancer Center, Philadelphia for originally providing these mice to M. Mahmood Hussain.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Gault, C.R.; Obeid, L.M.; Hannun, Y.A. An overview of sphingolipid metabolism: From synthesis to breakdown. Adv. Exp. Med. Biol. 2010, 688, 1–23. [Google Scholar]
  2. Lucki, N.C.; Sewer, M.B. Nuclear sphingolipid metabolism. Annu. Rev. Physiol. 2012, 74, 131–151. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Bikman, B.T.; Summers, S.A. Ceramides as modulators of cellular and whole-body metabolism. J. Clin. Investig. 2011, 121, 4222–4230. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Morad, S.A.; Cabot, M.C. Ceramide-orchestrated signalling in cancer cells. Nat. Rev. Cancer 2013, 13, 51–65. [Google Scholar] [CrossRef] [PubMed]
  5. Hla, T.; Dannenberg, A.J. Sphingolipid signaling in metabolic disorders. Cell Metab. 2012, 16, 420–434. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Shimabukuro, M.; Zhou, Y.T.; Levi, M.; Unger, R.H. Fatty acid-induced beta cell apoptosis: A link between obesity and diabetes. Proc. Natl. Acad. Sci. USA 1998, 95, 2498–2502. [Google Scholar] [CrossRef] [Green Version]
  7. Hu, W.; Bielawski, J.; Samad, F.; Merrill, A.H., Jr.; Cowart, L.A. Palmitate increases sphingosine-1-phosphate in C2C12 myotubes via upregulation of sphingosine kinase message and activity. J. Lipid Res. 2009, 50, 1852–1862. [Google Scholar] [CrossRef] [Green Version]
  8. Hu, W.; Ross, J.; Geng, T.; Brice, S.E.; Cowart, L.A. Differential regulation of dihydroceramide desaturase by palmitate versus monounsaturated fatty acids: Implications for insulin resistance. J. Biol. Chem. 2011, 286, 16596–16605. [Google Scholar] [CrossRef] [Green Version]
  9. Hannun, Y.A.; Obeid, L.M. Sphingolipids and their metabolism in physiology and disease. Nat. Rev. Mol. Cell Biol. 2018, 19, 175–191. [Google Scholar] [CrossRef]
  10. Ichikawa, S.; Sakiyama, H.; Suzuki, G.; Hidari, K.I.; Hirabayashi, Y. Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis. Proc. Natl. Acad. Sci. USA 1996, 93, 4638–4643. [Google Scholar] [CrossRef] [Green Version]
  11. Ichikawa, S.; Hirabayashi, Y. Glucosylceramide synthase and glycosphingolipid synthesis. Trends Cell Biol. 1998, 8, 198–202. [Google Scholar] [CrossRef] [PubMed]
  12. Lannert, H.; Bunning, C.; Jeckel, D.; Wieland, F.T. Lactosylceramide is synthesized in the lumen of the Golgi apparatus. FEBS Lett. 1994, 342, 91–96. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Burger, K.N.; van der Bijl, P.; van Meer, G. Topology of sphingolipid galactosyltransferases in ER and Golgi: Transbilayer movement of monohexosyl sphingolipids is required for higher glycosphingolipid biosynthesis. J. Cell Biol. 1996, 133, 15–28. [Google Scholar] [CrossRef] [PubMed]
  14. Budani, M.; Auray-Blais, C.; Lingwood, C. ATP-binding cassette transporters mediate differential biosynthesis of glycosphingolipid species. J. Lipid Res. 2021, 62, 100128. [Google Scholar] [CrossRef]
  15. Raggers, R.J.; van Helvoort, A.; Evers, R.; van Meer, G. The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane. J. Cell Sci. 1999, 112 Pt 3, 415–422. [Google Scholar] [CrossRef]
  16. Ishibashi, Y.; Kohyama-Koganeya, A.; Hirabayashi, Y. New insights on glucosylated lipids: Metabolism and functions. Biochim. Biophys. Acta 2013, 1831, 1475–1485. [Google Scholar] [CrossRef] [Green Version]
  17. Iqbal, J.; Walsh, M.T.; Hammad, S.M.; Cuchel, M.; Rader, D.J.; Hussain, M.M. ATP binding cassette family A protein 1 determines hexosylceramide and sphingomyelin levels in human and mouse plasma. J. Lipid Res. 2018, 59, 2084–2097. [Google Scholar] [CrossRef] [Green Version]
  18. Iqbal, J.; Walsh, M.T.; Hussain, M.M. ATP-Binding Cassette Transporter Family C Protein 10 Participates in the Synthesis and Efflux of Hexosylceramides in Liver Cells. Nutrients 2022, 14, 4401. [Google Scholar] [CrossRef]
  19. Chen, Z.S.; Hopper-Borge, E.; Belinsky, M.G.; Shchaveleva, I.; Kotova, E.; Kruh, G.D. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol. Pharmacol. 2003, 63, 351–358. [Google Scholar] [CrossRef]
  20. Bligh, E.G.; Dyer, W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37, 911–917. [Google Scholar] [CrossRef]
  21. Iqbal, J.; Walsh, M.T.; Hammad, S.M.; Cuchel, M.; Tarugi, P.; Hegele, R.A.; Davidson, N.O.; Rader, D.J.; Klein, R.L.; Hussain, M.M. Microsomal triglycerdie transfer protein transfers and determines plasma concentrations of ceramide and sphingomyelin but not glycosylceramide. J. Biol. Chem. 2015, 290, 25863–25875. [Google Scholar] [CrossRef] [PubMed]
  22. Jeckel, D.; Karrenbauer, A.; Burger, K.N.; van Meer, G.; Wieland, F. Glucosylceramide is synthesized at the cytosolic surface of various Golgi subfractions. J. Cell Biol. 1992, 117, 259–267. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Futerman, A.H.; Pagano, R.E. Determination of the intracellular sites and topology of glucosylceramide synthesis in rat liver. Biochem. J. 1991, 280 Pt 2, 295–302. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Malofeeva, E.V.; Domanitskaya, N.; Gudima, M.; Hopper-Borge, E.A. Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012, 72, 6457–6467. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Lavie, Y.; Cao, H.; Bursten, S.L.; Giuliano, A.E.; Cabot, M.C. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J. Biol. Chem. 1996, 271, 19530–19536. [Google Scholar] [CrossRef] [Green Version]
  26. Lavie, Y.; Cao, H.; Volner, A.; Lucci, A.; Han, T.Y.; Geffen, V.; Giuliano, A.E.; Cabot, M.C. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J. Biol. Chem. 1997, 272, 1682–1687. [Google Scholar] [CrossRef] [Green Version]
  27. Cabot, M.C.; Giuliano, A.E.; Volner, A.; Han, T.Y. Tamoxifen retards glycosphingolipid metabolism in human cancer cells. FEBS Lett. 1996, 394, 129–131. [Google Scholar] [CrossRef] [Green Version]
  28. Gouaze, V.; Yu, J.Y.; Bleicher, R.J.; Han, T.Y.; Liu, Y.Y.; Wang, H.; Gottesman, M.M.; Bitterman, A.; Giuliano, A.E.; Cabot, M.C. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol. Cancer Ther. 2004, 3, 633–639. [Google Scholar] [CrossRef]
  29. Callaghan, R.; Higgins, C.F. Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br. J. Cancer 1995, 71, 294–299. [Google Scholar] [CrossRef] [Green Version]
  30. Bekaii-Saab, T.S.; Perloff, M.D.; Weemhoff, J.L.; Greenblatt, D.J.; von Moltke, L.L. Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A. Biopharm. Drug Dispos. 2004, 25, 283–289. [Google Scholar] [CrossRef]
  31. Chapman, J.V.; Gouaze-Andersson, V.; Cabot, M.C. Expression of P-glycoprotein in HeLa cells confers resistance to ceramide cytotoxicity. Int. J. Oncol. 2010, 37, 1591–1597. [Google Scholar] [CrossRef] [PubMed]
  32. Kathawala, R.J.; Wang, Y.J.; Ashby, C.R., Jr.; Chen, Z.S. Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. Chin. J. Cancer 2014, 33, 223–230. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Hopper-Borge, E.A.; Churchill, T.; Paulose, C.; Nicolas, E.; Jacobs, J.D.; Ngo, O.; Kuang, Y.; Grinberg, A.; Westphal, H.; Chen, Z.S.; et al. Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10-/- mice. Cancer Res. 2011, 71, 3649–3657. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Zhao, H.; Huang, Y.; Shi, J.; Dai, Y.; Wu, L.; Zhou, H. ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC. Front. Pharmacol. 2018, 9, 1312. [Google Scholar] [CrossRef]
  35. Fabian, M.A.; Biggs, W.H., 3rd; Treiber, D.K.; Atteridge, C.E.; Azimioara, M.D.; Benedetti, M.G.; Carter, T.A.; Ciceri, P.; Edeen, P.T.; Floyd, M.; et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23, 329–336. [Google Scholar] [CrossRef]
  36. Hu, S.; Chen, Z.; Franke, R.; Orwick, S.; Zhao, M.; Rudek, M.A.; Sparreboom, A.; Baker, S.D. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin. Cancer Res. 2009, 15, 6062–6069. [Google Scholar] [CrossRef] [Green Version]
  37. Mukai, M.; Che, X.F.; Furukawa, T.; Sumizawa, T.; Aoki, S.; Ren, X.Q.; Haraguchi, M.; Sugimoto, Y.; Kobayashi, M.; Takamatsu, H.; et al. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. Cancer Sci. 2003, 94, 557–563. [Google Scholar] [CrossRef]
  38. Hirai, M.; Tanaka, K.; Shimizu, T.; Tanigawara, Y.; Yasuhara, M.; Hori, R.; Kakehi, Y.; Yoshida, O.; Ueda, K.; Komano, T.; et al. Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein. J. Pharmacol. Exp. Ther. 1995, 275, 73–78. [Google Scholar]
  39. Stefanovic, M.; Tutusaus, A.; Martinez-Nieto, G.A.; Barcena, C.; de Gregorio, E.; Moutinho, C.; Barbero-Camps, E.; Villanueva, A.; Colell, A.; Mari, M.; et al. Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma. Oncotarget 2016, 7, 8253–8267. [Google Scholar] [CrossRef] [Green Version]
  40. Trinchera, M.; Fabbri, M.; Ghidoni, R. Topography of glycosyltransferases involved in the initial glycosylations of gangliosides. J. Biol. Chem. 1991, 266, 20907–20912. [Google Scholar] [CrossRef]
  41. Lynch, D.V.; Criss, A.K.; Lehoczky, J.L.; Bui, V.T. Ceramide glucosylation in bean hypocotyl microsomes: Evidence that steryl glucoside serves as glucose donor. Arch. Biochem. Biophys. 1997, 340, 311–316. [Google Scholar] [CrossRef]
  42. Iqbal, J.; Rudel, L.L.; Hussain, M.M. Microsomal triglyceride transfer protein enhances cellular cholesteryl esterification by relieving product inhibition. J. Biol. Chem. 2008, 283, 19967–19980. [Google Scholar] [CrossRef] [PubMed]
  43. Liu, C.; Chen, Z.; Chen, Y.; Lu, J.; Li, Y.; Wang, S.; Wu, G.; Qian, F. Improving Oral Bioavailability of Sorafenib by Optimizing the “Spring” and “Parachute” Based on Molecular Interaction Mechanisms. Mol. Pharm. 2016, 13, 599–608. [Google Scholar] [CrossRef] [PubMed]
  44. Deng, Y.; Wu, W.; Ye, S.; Wang, W.; Wang, Z. Determination of cepharanthine in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. Pharm. Biol. 2017, 55, 1775–1779. [Google Scholar] [CrossRef] [PubMed]
Nutrients 15 00346 g001 550
Figure 1. Simplified schematic representation of sphingolipid biosynthesis. De novo sphingolipid synthesis is initiated by the condensation of palmitoyl-CoA and serine in the endoplasmic reticulum (ER), leading to the synthesis of ceramide (Cer). Cer is delivered to the Golgi by transport proteins or vesicular transport for synthesis of sphingomyelin (SM) on the lumenal side of Golgi by sphingomyelin synthase (SMS) or glucosylceramide (GlcCer) on the cytosolic side of Golgi by glucosylceramide synthase (GCS). GlcCer is then translocated to the Golgi lumen for the biosynthesis of complex glycosphingolipids (GSLs).
Figure 1. Simplified schematic representation of sphingolipid biosynthesis. De novo sphingolipid synthesis is initiated by the condensation of palmitoyl-CoA and serine in the endoplasmic reticulum (ER), leading to the synthesis of ceramide (Cer). Cer is delivered to the Golgi by transport proteins or vesicular transport for synthesis of sphingomyelin (SM) on the lumenal side of Golgi by sphingomyelin synthase (SMS) or glucosylceramide (GlcCer) on the cytosolic side of Golgi by glucosylceramide synthase (GCS). GlcCer is then translocated to the Golgi lumen for the biosynthesis of complex glycosphingolipids (GSLs).
Nutrients 15 00346 g001
Nutrients 15 00346 g002 550
Figure 2. Effect of tamoxifen on the efflux and synthesis of GlcCer. Huh-7 cells were treated with different doses (0–10 µM) of tamoxifen (Tam) for 17 h, labeled with 2 µM of C6-NBD ceramides in 10% FBS containing DMEM for 3 h, washed three times with 0.1% BSA containing DMEM, and then incubated with either 40 µg/mL BSA or HDL for 6 h to study sphingolipid efflux. Lipids in the media (A) and cells (B) were extracted and separated on TLC plate, and fluorescence in Cer, SM, and GlcCer bands was visualized with the PhosphorImager and quantified using ImageJ software (plotted below each TLC image). Values are plotted as replicates.
Figure 2. Effect of tamoxifen on the efflux and synthesis of GlcCer. Huh-7 cells were treated with different doses (0–10 µM) of tamoxifen (Tam) for 17 h, labeled with 2 µM of C6-NBD ceramides in 10% FBS containing DMEM for 3 h, washed three times with 0.1% BSA containing DMEM, and then incubated with either 40 µg/mL BSA or HDL for 6 h to study sphingolipid efflux. Lipids in the media (A) and cells (B) were extracted and separated on TLC plate, and fluorescence in Cer, SM, and GlcCer bands was visualized with the PhosphorImager and quantified using ImageJ software (plotted below each TLC image). Values are plotted as replicates.
Nutrients 15 00346 g002
Nutrients 15 00346 g003 550
Figure 3. Tamoxifen does not affect GCS activity. Liver homogenates (500 µg protein) from Abcc10+/+ and Abcc10−/− mice were incubated in triplicate with C6-NBD ceramides (3.3 µg/mL), phosphatidylcholine (100 µg/mL) and UDP-glucose (500 µM) in the presence of increasing concentrations of tamoxifen (0–10 µM) at 37 °C for 1 h. Lipids were extracted from the reaction mixture and separated on TLC plate. Fluorescence in Cer, SM, and GlcCer bands was visualized with the PhosphorImager (top) and quantified using ImageJ software (bottom). Values are plotted as replicates.
Figure 3. Tamoxifen does not affect GCS activity. Liver homogenates (500 µg protein) from Abcc10+/+ and Abcc10−/− mice were incubated in triplicate with C6-NBD ceramides (3.3 µg/mL), phosphatidylcholine (100 µg/mL) and UDP-glucose (500 µM) in the presence of increasing concentrations of tamoxifen (0–10 µM) at 37 °C for 1 h. Lipids were extracted from the reaction mixture and separated on TLC plate. Fluorescence in Cer, SM, and GlcCer bands was visualized with the PhosphorImager (top) and quantified using ImageJ software (bottom). Values are plotted as replicates.
Nutrients 15 00346 g003
Nutrients 15 00346 g004 550
Figure 4. Pre-treatment of Huh-7 cells with ABCC10 inhibitors affects synthesis and efflux of GlcCer. Huh-7 cells were pre-treated with 5 µM concentration of sorafenib or cepharanthine for 17 h, labeled with 2 µM of C6-NBD ceramides in 10% FBS containing DMEM for another 3 h to study sphingolipid synthesis. Media were collected, and cells were washed three times with 0.1% BSA containing DMEM and then used to extract lipids. Sphingolipids were separated in the media (A) and cells (B) on TLC, and fluorescence in Cer, SM, and GlcCer bands was visualized with the PhosphorImager (top) and quantified using ImageJ software (bottom). Values are plotted as replicates (mean ± SD), * p < 0.05, ** p < 0.01 and *** p < 0.001 compared with DMSO-treated cells.
Figure 4. Pre-treatment of Huh-7 cells with ABCC10 inhibitors affects synthesis and efflux of GlcCer. Huh-7 cells were pre-treated with 5 µM concentration of sorafenib or cepharanthine for 17 h, labeled with 2 µM of C6-NBD ceramides in 10% FBS containing DMEM for another 3 h to study sphingolipid synthesis. Media were collected, and cells were washed three times with 0.1% BSA containing DMEM and then used to extract lipids. Sphingolipids were separated in the media (A) and cells (B) on TLC, and fluorescence in Cer, SM, and GlcCer bands was visualized with the PhosphorImager (top) and quantified using ImageJ software (bottom). Values are plotted as replicates (mean ± SD), * p < 0.05, ** p < 0.01 and *** p < 0.001 compared with DMSO-treated cells.
Nutrients 15 00346 g004
Nutrients 15 00346 g005 550
Figure 5. Post-treatment of ABCC10 inhibitors affects only the efflux and not synthesis of GlcCer in Huh-7 cells. Huh-7 cells were labeled with 2 µM of C6-NBD ceramides in 10% FBS containing DMEM for 3 h to synthesize HexCer. Cells were washed three times with 0.1% BSA containing DMEM, and then incubated with 40 µg/mL of HDL in the presence of 5 µM sorafenib or cepharanthine for 6 h to study GlcCer efflux. Media and cells were collected to extract lipids. Lipids were separated in the media (A) and cells (B) on TLC plate and fluorescence in Cer, SM, and GlcCer bands was visualized with the PhosphorImager (top) and quantified using ImageJ software (bottom). Values are plotted as replicates (mean ± SD), *** p < 0.001 compared with DMSO-treated cells.
Figure 5. Post-treatment of ABCC10 inhibitors affects only the efflux and not synthesis of GlcCer in Huh-7 cells. Huh-7 cells were labeled with 2 µM of C6-NBD ceramides in 10% FBS containing DMEM for 3 h to synthesize HexCer. Cells were washed three times with 0.1% BSA containing DMEM, and then incubated with 40 µg/mL of HDL in the presence of 5 µM sorafenib or cepharanthine for 6 h to study GlcCer efflux. Media and cells were collected to extract lipids. Lipids were separated in the media (A) and cells (B) on TLC plate and fluorescence in Cer, SM, and GlcCer bands was visualized with the PhosphorImager (top) and quantified using ImageJ software (bottom). Values are plotted as replicates (mean ± SD), *** p < 0.001 compared with DMSO-treated cells.
Nutrients 15 00346 g005
Nutrients 15 00346 g006 550
Figure 6. ABCC10 inhibitors does not affect GCS activity. Liver homogenates (500 µg protein) from wild type mice were incubated with C6-NBD ceramides (3.3 µg/mL), phosphatidylcholine (100 µg/mL) and UDP-glucose (500 µM) in the presence of 5 µM concentration of either sorafenib or cepharanthine at 37 °C for 1 h. Lipids were extracted from the reaction mixtures, separated on TLC, fluorescence in Cer, SM, and GlcCer bands were visualized with the PhosphorImager (top), and quantified using ImageJ software (bottom). Values are plotted as replicates (mean ± SD).
Figure 6. ABCC10 inhibitors does not affect GCS activity. Liver homogenates (500 µg protein) from wild type mice were incubated with C6-NBD ceramides (3.3 µg/mL), phosphatidylcholine (100 µg/mL) and UDP-glucose (500 µM) in the presence of 5 µM concentration of either sorafenib or cepharanthine at 37 °C for 1 h. Lipids were extracted from the reaction mixtures, separated on TLC, fluorescence in Cer, SM, and GlcCer bands were visualized with the PhosphorImager (top), and quantified using ImageJ software (bottom). Values are plotted as replicates (mean ± SD).
Nutrients 15 00346 g006
Nutrients 15 00346 g007 550
Figure 7. Localization of ABCC10 with subcellular membranes. Liver homogenates from wildtype mouse were used to separate the ER, Golgi and cell membranes using Percoll density gradient ultracentrifugation. Western blot analysis of subcellular fractions was performed using specific antibodies against ABCC10 or housekeeper protein markers of Golgi (GM1340), cell membrane (Cadherin), cytoskeleton (Vimentin), and ER (Calreticulin).
Figure 7. Localization of ABCC10 with subcellular membranes. Liver homogenates from wildtype mouse were used to separate the ER, Golgi and cell membranes using Percoll density gradient ultracentrifugation. Western blot analysis of subcellular fractions was performed using specific antibodies against ABCC10 or housekeeper protein markers of Golgi (GM1340), cell membrane (Cadherin), cytoskeleton (Vimentin), and ER (Calreticulin).
Nutrients 15 00346 g007
Nutrients 15 00346 g008 550
Figure 8. Proposed schematic representation of GlcCer transport by ABCC10 under different cellular stimuli. Under normal conditions, (A) glucosylceramide synthase (GCS) present on the cytosolic side of the Golgi converts ceramide (Cer) to glucosylceramide (GlcCer), which may be either translocated to the lumen by Golgi membrane-bound ABCC10 for further glycosylation to form complex glycosphingolipids (GSLs) or effluxed to the media by cell membrane-bound ABCC10. Inhibition of Golgi membrane- and cell membrane-bound ABCC10 with sorafenib (B) blocks translocation of GlcCer to the lumen or media and, therefore, may result in the feedback inhibition of GCS, leading to less synthesis of GlcCer. Inhibition of cell membrane-bound ABCC10 with cepharanthine (C) may prevent only the efflux of GlcCer to the media and, thereby, results in increased accumulation of GlcCer in the cells.
Figure 8. Proposed schematic representation of GlcCer transport by ABCC10 under different cellular stimuli. Under normal conditions, (A) glucosylceramide synthase (GCS) present on the cytosolic side of the Golgi converts ceramide (Cer) to glucosylceramide (GlcCer), which may be either translocated to the lumen by Golgi membrane-bound ABCC10 for further glycosylation to form complex glycosphingolipids (GSLs) or effluxed to the media by cell membrane-bound ABCC10. Inhibition of Golgi membrane- and cell membrane-bound ABCC10 with sorafenib (B) blocks translocation of GlcCer to the lumen or media and, therefore, may result in the feedback inhibition of GCS, leading to less synthesis of GlcCer. Inhibition of cell membrane-bound ABCC10 with cepharanthine (C) may prevent only the efflux of GlcCer to the media and, thereby, results in increased accumulation of GlcCer in the cells.
Nutrients 15 00346 g008
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Iqbal, J.; Otaibi, A.A.; Mubarak, S.A.; Alqarni, A.; Bakillah, A. Differential Regulation of Glucosylceramide Synthesis and Efflux by Golgi and Plasma Membrane Bound ABCC10. Nutrients 2023, 15, 346. https://doi.org/10.3390/nu15020346

AMA Style

Iqbal J, Otaibi AA, Mubarak SA, Alqarni A, Bakillah A. Differential Regulation of Glucosylceramide Synthesis and Efflux by Golgi and Plasma Membrane Bound ABCC10. Nutrients. 2023; 15(2):346. https://doi.org/10.3390/nu15020346

Chicago/Turabian Style

Iqbal, Jahangir, Abeer Al Otaibi, Sindiyan Alshaikh Mubarak, Ali Alqarni, and Ahmed Bakillah. 2023. "Differential Regulation of Glucosylceramide Synthesis and Efflux by Golgi and Plasma Membrane Bound ABCC10" Nutrients 15, no. 2: 346. https://doi.org/10.3390/nu15020346

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop